8Saed GM, Ladin D, Olson J, et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based sindle-strand conformational polymorphism and DNA sequencing[J]. Arch Dermatol, 1998, 134(8): 1029-1032.
9Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa activation in gastric cancer cells[J]. Oncogene, 2001, 20:8009-8018.
3Kamb A, Gruis NA, Weaver J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 1994, 264 :436 - 440.
4Noborl T, Miura K, Wu DJ, et al. Deletions of the cyclin-depend-ent kinase-4 inhibitor gene in multiple human cancers. Nature,1994,368 : 753 - 756.
5Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res, 2001,264:42 - 55.
6Brissett AE, Sherris DA, Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg, 2001,17:263 - 272.
7Shaffer JJ, Taylor SC, Cook F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol, 2002 ,46Supp1:63 - 97.
8Giovannini UM. Treatment of scars by steroid injections, Wound Repair Regen, 2002,10 : 116 - 117.
9Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep, 2002; 4(2): 136.
